抗感染活性骨治疗慢性血源性骨髓炎临床应用研究

目的]观察和研究抗感染活性骨(anti-infective reconstituted bone xenograft,ARBX)I期植骨治疗慢性血源性骨髓炎的疗效。方法]在获得总后卫生部军内临床试用研究许可的基础上,自2001年9月起将ARBX用于临床治疗慢性血源性骨髓炎24例,对其中17例获得12个月以上系统随访的患者进行疗效分析。结果]17例中除1例骨髓炎未能治愈,1例骨髓炎治愈后复发,1例骨髓炎合并大段骨缺损在术后发生骨不连外;其余14例骨髓炎均获得完全治愈,病变部位均获得确实骨修复,无骨髓炎复发。本组慢性骨髓炎总治愈率为82.4%,远高于传统治疗方法。结论]ARBX具有高效诱导成骨活性和强效抗感染能力,能I期植骨有效治疗慢性血源性骨髓炎。

Clinical study on anti-infective reconstituted bone xenograft for treatmeat of chronic hematogenous osteomyelitis

Objective] To study the effect of anti-infective reconstituted bone xenograft(ARBX)on treating chronic hematogenous osteomyelitis as one-stage grafting.Method]ARBX was used to treat 24 cases of chronic hematogenous osteomyelitis as one-stage grafting after debridement since September of 2001,17 cases of which were followed up for an average period of 34 months(range,12 to 79 months).Result]Except 1 case failed to cure,and 1 resulted in recurrence of infection,and 1 with large segmental bone defect nonunion post-operatively,other 14 cases were cured,the cure rate was 82.4% which was better than traditional therapy.Conclusion]ARBX has high osteoinductive activity and enhanced anti-infective capability,which enables it to be used as primary grafting to treat chronic hematogenous osteomyelitis.